New hope for Tough-to-Treat leukemia: experimental drug added to standard chemo
NCT ID NCT03330821
Summary
This study is testing a new drug called pevonedistat, given alongside standard chemotherapy drugs, for adults newly diagnosed with high-risk acute myeloid leukemia (AML). The main goals are to find the safest and most effective dose of the new combination and to see if it helps more patients achieve remission. It is for patients who are considered fit for intensive chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA WITH MYELODYSPLASIA-RELATED CHANGES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Los Angeles County-USC Medical Center
Los Angeles, California, 90033, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Arizona Cancer Center - North Campus
Tucson, Arizona, 85724, United States
-
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, 33136, United States
Conditions
Explore the condition pages connected to this study.